Living meta-analysis and evidence synthesis of therapies for COVID-19

 

• COVID 19 hospitalized
• COVID 19 all comers
• COVID-19 mild to moderate
• COVID-19 severe or critically
• COVID 19 outpatients
• COVID-19 (hospitalized or not)
• COVID-19 prophylaxis (children)
• COVID-19 prophylaxis (excluding children)
• infections other than COVID-19
• Long COVID-19
• preventing respiratory virus transmission
• secondary prevention

 

• adjuvant therapies
• anticoagulant
• anticoagulant, curative dose
• anticoagulant, prophylactic dose
• anticoagulation, intermediate prophylactic dose
• Bivalirudin
• heparin at therapeutic dose
• P2Y12 inhibitors
• hyperbaric oxygen
• nintedanib
• respiratory support
• anti-inflammatoty and immuno-therapy
• anti-inflammatory therapies
• anti GM-CSF
• mavrilimumab
• colchicine
• naproxen, ibuprofen
• stem cells
• vilobelimab (IFX-1)
• corticosteroids
• dexamethasone
• Dexamethasone 12mg
• Hydrocortisone
• methylprednisolone
• Immunostimulants drugs
• anti-PD-1 antibody
• CD24Fc
• convalescent plasma treatment
• immunoglobulin therapy
• interferon
• IFN beta-1a
• IFN beta-1b
• neutralizing antibody
• equine polyclonal antibodies INM005
• XAV-19
• Immunosuppressants drugs
• abatacept
• adalimumab
• anakinra
• anti-interleukin-6
• clazakizumab
• Levilimab
• sarilumab
• sarilumab azithromycin hydroxychloroquine
• sarilumab high dose (400mg)
• sarilumab low dose (200mg)
• siltuximab
• tocilizumab
• canakinumab
• cenicriviroc
• complement inhibitors
• eculizumab
• infliximab
• itolizumab
• jakotinib
• janus kinase (JAK) inhibitor
• baricitinib
• ruxolitinib
• TD-0903
• TD-0903 10mg
• TD-0903 1mg
• TD-0903 3mg
• tacrolimus
• thalidomide
• Kinase inhibitors
• acalabrutinib
• imatinib
• sargramostim
• statins
• Atorvastatin
• thymosin
• antiviral and associated therapy
• azithromycin
• chloroquine and derivatives
• chloroquine
• hydroxychloroquine
• favipiravir
• hydroxychloroquine plus macrolides
• ivermectin
• leronlimab
• lopinavir / ritonavir plus ribavirin
• lopinavir/ritonavir
• Lopinavir/ritonavir plus hydroxychloroquine
• opaganib
• remdesivir
• sofosbuvir and daclatasvir
• zinc
• miscellaneous
• alpha lipoic acid
• aviptadil
• cytokine adsorption
• kinin-kallikrein inhibitors
• pyridostigmine
• Oral antidiabetic drugs
• DPP-4 inhibitor
• Renin-angiotensin-system-acting agents
• angiotensin-(1-7)
• Vitamins
• vitamin C
• Vitamin D
• All treatment (not recommended)

    Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS) see more...